Answers are grounded in this paper and cite their sources.
Evaluates new therapies in bone sarcomas, suggesting improved treatment options.
Summary Bone sarcomas are rare, biologically heterogeneous malignancies in which progress in systemic therapy has historically been slow. In Ewing sarcoma, dose-dense VDC/IE (vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide) has become the global induction standard, with EURO-EWING 2012 and AEWS0031 demonstrating survival benefits through interval compression. Contemporary international platforms, including INTER-EWING and iEuroEwing, now provide harmonized, biomarker-integrated frameworks to evaluate novel agents, radiotherapy optimization, and maintenance strategies. In relapsed disease, the rEECur trial has redefined standards by identifying high-dose ifosfamide as the most active salvage regimen, while deprioritizing less effective combinations; additional rational combinations such as ifosfamide plus lenvatinib and trabectedin plus irinotecan are under active investigation. In osteosarcoma, MAP (high-dose methotrexate, doxorubicin, cisplatin) chemotherapy remains the first-line standard, and postoperative intensification with MAPIE (MAP, ifosfamide, etoposide) has not improved outcomes. Targeted multikinase inhibitors (TKIs), including cabozantinib and regorafenib, provide meaningful but time-limited activity in refractory disease. A large ongoing National Cancer Institute (NCI) phase II/III trial is currently evaluating the addition of cabozantinib to frontline MAP in newly diagnosed patients. Antibody–drug conjugates (ADCs) targeting LRRC15 and B7-H3 represent further promising strategies. Chondrosarcoma remains largely chemoresistant, but targeted approaches are beginning to alter the therapeutic landscape. Isocitrate dehydrogenase (IDH) 1 inhibition with ivosidenib has shown durable disease control, and death receptor (DR) 5 agonism with INBRX-109 has delivered the first positive randomized systemic therapy signal in conventional chondrosarcoma. Continued international collaboration and biomarker-driven trial design are essential to translate these advances into clinical practice.
No takes yet. Share an insight, caveat, or question.
Joanna Szkandera (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: